Vor Biopharma
Vor Biopharma raises $110M Series C at $700M valuation
Quick Facts
Vor Biopharma: Series C Funding Round
Vor Biopharma has successfully raised $110M in Series C funding, reaching a valuation of $700M.
Company Overview
Engineering hematopoietic stem cells
Funding Details
The Series C round was led by 5AM Ventures, with participation from Fidelity, SR One, Novartis Venture Fund, Cormorant Asset Management.
Company Information
- Headquarters: 200 Sidney Street, Cambridge, MA 02139
- Founded: 2015
- Employees: 150+
- Category: Biotech
Investment
Vor Biopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- 5AM Ventures: Verified investor in Series C
- Fidelity: Verified investor in Series C
- SR One: Verified investor in Series C
- Novartis Venture Fund: Verified investor in Series C
- Cormorant Asset Management: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...